Compare Amplify Transformational Data Sharing ETF (BLOK) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Transformational Data Sharing ETF vs Sanofi SA — how do they compare? Amplify Transformational Data Sharing ETF trades at $61.14, while Sanofi SA trades at $43.15 (market cap $105.09B). The key difference: Sanofi SA pays a 5.5% dividend while Amplify Transformational Data Sharing ETF pays none, and Amplify Transformational Data Sharing ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| BLOK | SNY | |
|---|---|---|
52-Week High | $74.10 | $52.34 |
52-Week Low | $47.36 | $41.33 |
Market Cap | — | $105.09B |
Sector | — | Health |
Enterprise Value | — | $121.57B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BLOK trades at $60.81, down 2.95% on the day, with a bearish technical signal from moving averages while oscillators are neutral. The stock faces resistance near $62 and support at $60. Recent news highlights its diversified blockchain economy exposure, including miners and enterprise adopters, though financial ratios like P/E and P/S are not provided in the current dataset.
The outlook remains cautious due to technical bearishness and increased reliance on Bitcoin performance, posing volatility risks. Investment opportunity lies in broad blockchain sector exposure, but risks include market sentiment shifts and lack of near-term catalysts, warranting close monitoring of earnings and sector trends.
SNY trades at $44.00, up 1.15% with a bullish technical signal. Recent FDA approvals for Sarclisa and Nexviazyme highlight pipeline strength. Q1 2026 EPS beat expectations at $1.10 versus $1.06. Revenue grew to $46.72B in 2025 with net income margin of 15.95%. Analyst consensus is mixed with 44% buy ratings. The stock shows solid profitability with ROE at 10.29% and manageable debt levels.
Outlook is positive driven by drug approvals and earnings beats, but EU antitrust probes pose regulatory risks. Valuation at P/E 19.51 is reasonable versus peers. Institutional sentiment is cautious with 52% hold ratings. Key catalysts include Q2 2026 results and Sarclisa commercial rollout. Risks include competition and patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amplify Transformational Data Sharing ETF
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
